Haselwanter, Patrick
Scheiner, Bernhard
Balcar, Lorenz
Semmler, Georg
Riedl-Wewalka, Marlene
Schmid, Monika
Reiberger, Thomas
Zauner, Christian
Schneeweiss-Gleixner, Mathias
Article History
Received: 2 November 2023
Accepted: 8 May 2024
First Online: 17 May 2024
Competing interests
: The authors have nothing to disclose regarding the work under consideration for publication. Conflicts of interests outside the submitted work: B.S. received travel support from AbbVie, Ipsen, and Gilead; G.S. received travel support from Gilead; T.R. received grant support from Abbvie, Boehringer-Ingelheim, Gilead, Intercept, MSD, Myr Pharmaceuticals, Philips Healthcare, Pliant, Siemens and W. L Gore & Associates; speaking honoraria from Abbvie, Gilead, Intercept, Roche, MSD, W. L Gore & Associates; consulting/advisory board fee from Abbvie, Astra Zeneca, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Resolution Therapeutics, Siemens; and travel support from Abbvie, Boehringer-Ingelheim, Gilead and Roche.